医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

GenesisCare Appoints New Executive Manager Furthering Rapid Growth & Acquisitions

2022年02月24日 AM04:00
このエントリーをはてなブックマークに追加


 

SYDNEY

GenesisCare, the largest provider of integrated cancer care in Australia and globally, has today welcomed Richard Lizzio as its new Executive Manager for Oncology Australia.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220223005517/en/

Richard Lizzio, GenesisCare Executive Manager, Oncology Australia (Photo: Business Wire)

Richard Lizzio, GenesisCare Executive Manager, Oncology Australia (Photo: Business Wire)

Richard joins GenesisCare with 20 years of experience across hospitals and healthcare, having held senior operational and leadership roles within St Vincent’s Health Australia, Uniting Care, Healthscope and Ramsay Health Care.

Richard joins at an exciting time of rapid growth and expansion for GenesisCare in Australia. GenesisCare has been implementing a national integrated cancer care program to combat disrupted care pathways caused by COVID-19. GenesisCare recently opened three new world-class integrated cancer centres in areas of high unmet need and acquired the largest medical oncology provider in South Australia, Adelaide Oncology & Haematology.

GenesisCare’s Global Chief Operating Officer, Michael O’Sullivan, said: “We’re delighted to welcome Richard as GenesisCare’s new Oncology Australia Executive Manager. Richard has a wealth of experience in healthcare, and an impressive track record of re-imagining next-generation business models to achieve the best possible outcomes for patients. He will play a key role as we enter an exciting new stage of growth and development in our business.”

Richard began his career in healthcare at Ramsay Health Care, working for eight years in various hospital CEO positions in Queensland, later joining Healthscope to manage nine of its private hospitals. Since then, Richard has held several leadership roles at UnitingCare Queensland, Icon Group, and St Vincent’s Health Australia.

Newly appointed Executive Manager for Oncology Australia, Richard Lizzio, said: “I have had the great pleasure of working closely with GenesisCare’s clinicians and executive team in my previous roles and have seen first-hand the innovative, world-class care they provide to cancer patients.

“I am truly excited by the opportunity this role brings. I look forward to leading GenesisCare’s Australian business as we scale our integrated cancer care program, expand our medical oncology and theranostics portfolio, and embark on new partnerships with other leading healthcare providers.

“GenesisCare’s continued growth and investment in new centres, technology, and partnerships is founded on the company’s core belief that patients should have access to great care that achieves the best possible outcomes, close to home,” said Mr Lizzio.

In his new role, Richard will guide the expansion of GenesisCare’s integrated cancer treatment centres across Australia and will drive several new hospital partnerships. In the past six months, GenesisCare has opened three new integrated centres – GenesisCare North Shore (NSW), GenesisCare Maitland (NSW), and GenesisCare Murdoch (WA) – with Norwest Sydney (NSW) currently nearing completion. Over the next two years, GenesisCare has a strong pipeline of new centre openings including Campbelltown (NSW), Frenches Forest (NSW) and two centres in Adelaide (SA).

Mr Lizzio will also work in close partnership with GenesisCare’s new Chief Medical Officer, Dr Marie Burke, OAM. Dr Burke is a highly regarded radiation oncologist with more than 30 years’ experience, including a decade at GenesisCare. She was recognised for her service to medicine and the community in the 2022 Australia Day Honours list.

Spokespeople available:

  1. Richard Lizzio, Executive Manager for Oncology Australia, GenesisCare
  2. Michael O’Sullivan, Global Chief Operating Officer, GenesisCare

About GenesisCare:

Headquartered in Sydney, Australia, GenesisCare is a global healthcare company and one of the world’s largest integrated oncology organisations. The company’s purpose is to design care experiences that get the best possible life outcomes. This is grounded in the belief that care should be focused on the individual, not the condition.

GenesisCare is the world’s largest provider of radiotherapy – a vital treatment option for cancer patients – and provides patients with access to diagnostics, medical oncology, surgical oncology, radiotherapy, and novel therapies alongside the ability to participate in the latest clinical trials. With a growing research and trials program numbering more than 150 clinical trials, a contract research organisation, and global innovation programs focused on precision medicine and novel therapies, GenesisCare aims to bring new therapies to more patients in need in a more affordable way.

Every year, GenesisCare clinical teams see more than 400,000 people at more than 440 locations, for cancer treatment, that includes more than 300 locations in the U.S., 40 locations in Australia, 14 in the UK, and 16 in Spain, with more than 30 new centres under development. The organisation employs more than 6000 highly trained physicians, healthcare professionals and support staff across Australia, Europe and the U.S. GenesisCare also offers cardiology and sleep services at more than 80 locations across Australia. For more information, visit genesiscare.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20220223005517/en/

CONTACT

For media enquiries

Bronte Kerr – Media Relations Manager

Email: bronte.kerr@genesiscare.com

Phone: +61 428 298 121

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Xlear Files Amended Answer to the Government’s Lawsuit on COVID-19 Statements; Provides Still More Data In Support of Xlear’s Use as Additional Layer of Protection
  • EpiAxis Therapeutics & Peptilogics Enter Strategic Drug Discovery Partnership
  • BeiGene Announces Strategic Alliance with Ontada to Improve U.S. Community Oncology Care
  • ENHERTU® Significantly Delayed Disease Progression in DESTINY-Breast02 Phase 3 Trial Versus Physician’s Choice of Treatment in Patients with HER2 Positive Metastatic Breast Cancer
  • Arbitrator Rules in Favor of Daiichi Sankyo in Dispute with Seagen